Reference ustekinumab was originally approved by the FDA in 2009. Wezlana (ustekinumab-auub) was approved last October.

Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan member will pay $0 out ...

VX-880 is an allogeneic stem cell-derived islet cell therapy that has been able to control blood glucose as well as natural ...

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

Neither party wants to be perceived as threatening Medicare. The Biden administration has taken steps to reduce payment to ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Dr. Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

The FDA approved IntraBio Inc.'s Aqneursa (levacetylleucine) yesterday for the treatment of ultra rare neurodegenerative ...

Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.

The patient panels of physicians underrepresented in medicine (URiM) showed that they had greater odds of being a Medicaid ...